MFN1 (Mitofusin-1) is a dynamin-like GTPase protein located in the outer mitochondrial membrane that plays a critical role in mitochondrial fusion and cellular energy metabolism. It is encoded by the MFN1 gene and is essential for maintaining mitochondrial network integrity.
MFN1 contains:
- N-terminal GTPase domain (responsible for GTP hydrolysis)
- Middle domain (involved in protein-protein interactions)
- Two transmembrane domains (anchoring to mitochondrial membrane)
- C-terminal GTPase effector domain (regulates GTPase activity)
The protein undergoes conformational changes during the fusion process, transitioning between monomeric, dimeric, and oligomeric states.
MFN1 mediates the initial tethering of adjacent mitochondria through:
- Trans-interactions: MFN1 molecules on opposing mitochondria interact via their HR2 domains
- GTP hydrolysis: Induces conformational changes that drive membrane fusion
- Inner membrane mixing: Works coordinately with OPA1 for complete fusion
- Maintains mitochondrial DNA (mtDNA) distribution
- Preserves respiratory chain function
- Regulates mitochondrial metabolite transport
- Influences ATP production efficiency
- Facilitates mitochondrial turnover through fusion/fission dynamics
- Enables selective removal of damaged mitochondria via mitophagy
- Prevents accumulation of dysfunctional mitochondria
- Mitochondrial dysfunction: MFN1 levels are reduced in AD brains, leading to fragmented mitochondria
- Amyloid-beta: Aβ toxicity directly interacts with MFN1, impairing fusion
- Tau pathology: Hyperphosphorylated tau disrupts mitochondrial transport and distribution
- Bioenergetic deficit: Impaired fusion leads to decreased OXPHOS capacity
- LRRK2 interaction: Mutant LRRK2 (G2019S) disrupts MFN1 function
- PINK1/Parkin pathway: MFN1 is a substrate for Parkin-mediated mitophagy
- Alpha-synuclein: Aggregation affects mitochondrial dynamics proteins
- TDP-43 pathology: Disrupts mitochondrial network dynamics
- C9orf72: DPRs may affect mitochondrial fusion machinery
- Energy failure: Motor neurons particularly vulnerable to mitochondrial dysfunction
- CMT2A: MFN2 mutations cause axonal neuropathy; MFN1 may have compensatory role
- Targeting GTPase activity: Compounds that enhance MFN1 function
- Allosteric modulators: Drugs stabilizing MFN1 conformational states
- AAV-MFN1: Viral delivery to restore mitochondrial fusion
- CRISPR activation: Upregulating endogenous MFN1 expression
- Antioxidants: Protect MFN1 from oxidative damage
- Anti-aggregation: Prevent proteins that interfere with MFN1 function